Aurobindo Pharma Limited

Aurobindo Pharma Limited

Aurobindo Pharma Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, with a profit before tax of ₹10,080.8 million and a profit after tax of ₹7,372.2 million. The company has also announced a proposal to file a Scheme of Amalgamation for the merger of its subsidiaries with a wholly-owned subsidiary.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about a copy of a newspaper publication regarding the dispatch of the Notice of 39th Annual General Meeting and Annual Report for the financial year 2025-26, and a special window for re-lodging transfer and dematerialization of physical securities.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about dispatch of a letter providing a web-link of the Integrated Annual Report 2025-26 to those Members who have not registered their e-mail addresses.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange regarding Notice of 39th Annual General Meeting to be held on August 27, 2026, to consider and approve various resolutions including the reappointment of directors, dividend declaration, and appointment of secretarial auditor.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the Copy of Newspaper Publication regarding the 39th Annual General Meeting of the Company to be held on August 27, 2026, through Video Conferencing / Other Audio-Visual Means.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has announced the date of its 39th Annual General Meeting, scheduled to be held on August 27, 2026, through video conferencing. The notice and integrated annual report for the financial year 2025-26 will be sent to registered shareholders and made available on the company's website.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the schedule of Earnings Call to be held on August 6, 2026, to discuss the unaudited financial results for the first quarter ended June 30, 2026.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has entered into a non-exclusive voluntary license agreement with MSD (Merck & Co., Inc.) to supply generic alimatravir to 129 Low- & Middle-Income Countries (LMICs) for HIV prevention, subject to regulatory approvals.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has acquired 80% ownership in A1 Biochem Labs (India) Private Limited, India, and A1 Biochem Labs LLC, USA, for an enterprise value of USD 17 million, expanding its presence in the life cycle of Active Pharmaceutical Ingredients (API) business.

Aurobindo Pharma Limited

Aurobindo Pharma Limited's wholly owned subsidiary CuraTeQ Biologics Private Limited has received ANVISA approval for its biosimilars manufacturing facility in Hyderabad, strengthening the company's capability to supply biosimilar products to the Brazilian and broader Latin American markets.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the incorporation of a new wholly owned step-down subsidiary in Indonesia, PT Auro Pharm Indonesia, to undertake manufacturing operations.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, certifying the details of securities dematerialized/rematerialized during the quarter ended June 30, 2026, have been furnished to all the stock exchanges where the shares of the Company are listed.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has completed the transfer of its domestic branded generic pharmaceutical formulations products business to Auropharm Limited, a wholly owned subsidiary, effective July 1, 2026.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has completed the acquisition of Lannett Company, Inc. through its US subsidiary, Aurobindo Pharma USA Inc.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about Completion of US FDA Inspection at Auroactive Pharma Private Limited, a wholly owned subsidiary of the Company. The inspection concluded with 2 observations and will be responded to within the stipulated time.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the completion of the execution of a solar power purchase agreement and acquired a 26% stake in Swarnaakshu Solar Power Private Limited.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Aurobindo Pharma Limited

Aurobindo Pharma USA, a wholly-owned subsidiary of Aurobindo Pharma Limited, has received U.S. Federal Trade Commission (FTC) approval to acquire Lannett Company LLC for $250 million. This acquisition, set to close by June 2026, will significantly expand Aurobindo's portfolio of complex generic and non-opioid controlled substances and add a U.S.-based manufacturing facility. The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share and generate meaningful cost efficiencies and synergies, supporting sustainable long-term growth.

Aurobindo Pharma Limited

Aurobindo Pharma Limited announced the completion of a US FDA Pre-Approval Inspection (PAI) at its 100% stepdown subsidiary, Eugia Steriles Private Limited. The inspection, held from June 10 to June 19, 2026, at the facility in Andhra Pradesh, concluded with five observations. The company has stated it will respond to these observations within the stipulated timeframe. This update is significant for investors as a successful resolution of these observations is crucial for securing FDA approvals for new products manufactured at this facility, impacting the company's future revenue potential from the US market.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has announced a disclosure under Regulation 31(4) of the SEBI Takeover Regulations. Promoter K. Nithyananda Reddy, on behalf of the promoter and promoter group, declared that they have not made any new encumbrances (such as pledges) on their shares in the company during the financial year ended March 31, 2026. This declaration confirms that no additional shares were pledged beyond what was already disclosed to the stock exchanges. For investors, this signifies transparency from the promoters regarding their shareholdings, providing reassurance about the stability of their stake.